Lexaria product shows promise
Okanagan Edge Staff - Dec 03, 2020 - Biz Releases

Photo: Contributed

A Kelowna bioscience company that specializes in drug delivery platforms has received good news on the research front.

Lexaria Bioscience announced this week that its DehydraTECH technology significantly improved delivery in study animals of representative drugs from two classes of antiviral therapies under investigation against SARS-CoV-2/COVID-19 and already in use against HIV/AIDS.

“We are very pleased to have demonstrated improvements in DehydraTECH’s delivery of antiviral drugs in animal bloodstream in our very first attempt to do so,” Lexaria CEO  Chris Bunka said in a press release. “DehydraTECH is a powerful technology that has now been shown effective through animal testing with antiviral drugs, nicotine and cannabinoids, demonstrating its versatility to enhance delivery of lipophilic drugs to the bloodstream.”

The animals demonstrated excellent safety and tolerability upon dosing with the DehydraTECH formulations, according to Lexaria, displaying normal activity and behaviour throughout the study with no adverse effects.


All Biz Releases Stories